First cell-based gene therapy approved for multiple myeloma

Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.

Medical research

Metabolic response behind reduced cancer cell growth

Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells' ...

page 1 from 17